Program
reproxalap
Also written as “Reproxalap Ophthalmic Solution (0.25%)”, “Reproxalap Ophthalmic Solution (0.5%)” and “ADX-102 Ophthalmic Solution (0.5%)”.
Its studies are mostly in Dry Eye Syndromes · Conjunctivitis, Allergic · Alopecia Areata · Uveitis, Anterior, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aldeyra Therapeutics | 200 open or running | phase 3since Apr 4, 2017 | Dec 14, 2016 | none ahead |
| Aldena Therapeutics | 11 open or running | phase 2since Jan 22, 2025 | Jan 22, 2025 | Nov 2026phase 2 · NCT06826196 |
Also a collaborator on its studies: ORA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Dec 14, 2016.
- Oct 3, 2018Phase 2 study in Conjunctivitis, AllergicAldeyra Therapeutics · NCT03709121 · 70 enrolled · Canada
- Mar 15, 2019Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT03879863 · 422 enrolled · United States
- Dec 19, 2019Phase 3 study in Conjunctivitis, AllergicAldeyra Therapeutics · NCT04207736 · 95 enrolled · Canada
- Dec 14, 2020Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT04674358 · 329 enrolled · United States
- Jan 25, 2021Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT04735393 · 757 enrolled · United States
- Jul 12, 2021Phase 2 study in Dry Eye SyndromesAldeyra Therapeutics · NCT04971031 · 158 enrolled · United States
- Sep 13, 2021Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT05062330 · 361 enrolled · United States
- Oct 18, 2021Phase 2 study in Dry Eye SyndromesAldeyra Therapeutics · NCT05102409 · 56 enrolled · Canada
- Feb 1, 2022Phase 3 study in Conjunctivitis, AllergicAldeyra Therapeutics · NCT05234554 · 131 enrolled · Canada
- Jun 15, 2022Phase 2 study in Dry Eye SyndromesAldeyra Therapeutics · NCT05424549 · 63 enrolled · Canada
- Apr 25, 2024Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT06389214 · 132 enrolled · Canada
- May 17, 2024Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT06424444 · 421 enrolled · United States
- Jul 2, 2024Phase 3 study in Dry Eye SyndromesAldeyra Therapeutics · NCT06493604 · 116 enrolled · United States
- Jan 22, 2025Aldena Therapeutics's first study: phase 2 study in Alopecia AreataNew to Aldena TherapeuticsAldena Therapeutics · NCT06826196 · 9 enrolled · United States, Canada
Ahead
- Nov 2026Primary completion: phase 2 study in Alopecia AreataAldena Therapeutics · NCT06826196
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06826196Alopecia Areata · United States, Canada | 2 | Active, not recruiting | Aldena Therapeutics | Nov 2026 | 9 |
| NCT06493604Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Feb 27, 2025 | 116 |
| NCT06424444Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Nov 3, 2024 | 421 |
| NCT06389214Dry Eye Syndromes · Canada | 3 | Completed | Aldeyra Therapeutics | Jun 11, 2024 | 132 |
| NCT05424549Dry Eye Syndromes · Canada | 2 | Completed | Aldeyra Therapeutics | May 9, 2022 | 63 |
| NCT05234554Conjunctivitis, Allergic · Canada | 3 | Completed | Aldeyra Therapeutics | Apr 22, 2023 | 131 |
| NCT05102409Dry Eye Syndromes · Canada | 2 | Completed | Aldeyra Therapeutics | Oct 25, 2021 | 56 |
| NCT05062330Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Mar 4, 2022 | 361 |
| NCT04971031Dry Eye Syndromes · United States | 2 | Completed | Aldeyra Therapeutics | Sep 8, 2021 | 158 |
| NCT04735393Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Oct 11, 2022 | 757 |
| NCT04674358Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Sep 12, 2021 | 329 |
| NCT04207736Conjunctivitis, Allergic · Canada | 3 | Completed | Aldeyra Therapeutics | Feb 16, 2021 | 95 |
| NCT03879863Dry Eye Syndromes · United States | 3 | Completed | Aldeyra Therapeutics | Oct 4, 2019 | 422 |
| NCT03709121Conjunctivitis, Allergic · Canada | 2 | Completed | Aldeyra Therapeutics | Mar 20, 2019 | 70 |
| NCT03660878Conjunctivitis, Allergic · United States | 2 | Completed | Aldeyra Therapeutics | Nov 19, 2019 | 52 |
| NCT03494504Conjunctivitis, Allergic · United States | 3 | Completed | Aldeyra Therapeutics | Nov 5, 2018 | 318 |
| NCT03445650Sjogren-Larsson Syndrome · United States | 3 | Completed | Aldeyra Therapeutics | Jan 18, 2020 | 11 |
| NCT03404115Dry Eye Syndromes · United States | 2 | Completed | Aldeyra Therapeutics | Jul 11, 2018 | 300 |
| NCT03162783Dry Eye Syndromes · United States | 2 | Completed | Aldeyra Therapeutics | Jul 6, 2017 | 51 |
| NCT03131154Non-infectious Anterior Uveitis · United States | 3 | Completed | Aldeyra Therapeutics | Apr 19, 2019 | 123 |
| NCT03012165Conjunctivitis, Allergic · United States | 2 | Completed | Aldeyra Therapeutics | May 2017 | 154 |
How it is read
Names in the registry
- “Reproxalap Ophthalmic Solution (0.25%)”, 15 entries
- “Reproxalap Ophthalmic Solution (0.5%)”, 3 entries
- “ADX-102 Ophthalmic Solution (0.5%)”, 2 entries
- “ALD-102 Solution”, 1 entry
- “Reproxalap ophthalmic solution (0.25%)”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 12 studies
- Conjunctivitis, Allergic, 6 studies
- Alopecia Areata, 1 study
- Uveitis, Anterior, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.